BAN2401 - Lecanemab - Alzheimer Disease Drug Brochure

In Alzheimer’s disease soluble, toxic amyloid beta aggregates are believed to contribute to the neurodegenerative process. Lecanemab, a anti amyloid-beta protofibril antibody, selectively binds to these forms of amyloid beta and eliminates them. The antibody’s unique profile is highly selective for amyloid beta oligomers/protofibrils in the brain. BioArctic’s belief is that lecanemab’s unique binding profile is important and differentiates it from other amyloid beta antibodies.